161 related articles for article (PubMed ID: 32829645)
1. Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options.
Dubé K; Campbell DM; Perry KE; Kanazawa JT; Saberi P; Sauceda JA; Poteat T; Evans D
AIDS Res Hum Retroviruses; 2020 Dec; 36(12):1054-1058. PubMed ID: 32829645
[TBL] [Abstract][Full Text] [Related]
2. The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.
Dubé K; Eskaf S; Evans D; Sauceda J; Saberi P; Brown B; Averitt D; Martel K; Meija M; Campbell D; Barr L; Kanazawa J; Perry K; Patel H; Luter S; Poteat T; Auerbach JD; Wohl DA
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):324-348. PubMed ID: 31608651
[TBL] [Abstract][Full Text] [Related]
3. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
Mantsios A; Murray M; Karver TS; Davis W; Galai N; Kumar P; Swindells S; Bredeek UF; García RR; Antela A; Gomis SC; Bernáldez MP; Czarnogorski M; Hudson K; Walters N; Kerrigan D
BMC Health Serv Res; 2021 Mar; 21(1):255. PubMed ID: 33743684
[TBL] [Abstract][Full Text] [Related]
4. "Cure" Versus "Clinical Remission": The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication.
Fridman I; Ubel PA; Blumenthal-Barby J; England CV; Currier JS; Eyal N; Freedberg KA; Halpern SD; Kelley CF; Kuritzkes DR; Le CN; Lennox JL; Pollak KI; Zikmund-Fisher BJ; Scherr KA
AIDS Behav; 2020 Jul; 24(7):2054-2061. PubMed ID: 31900813
[TBL] [Abstract][Full Text] [Related]
5. U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment.
Graham SM; Barthold D; Hauber B; Brah AT; Saldarriaga E; Collier AC; Ho RJY; ; Marconi VC; Simoni JM
J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26099. PubMed ID: 37439051
[TBL] [Abstract][Full Text] [Related]
6. Assessment of satisfaction with antiretroviral drugs and the need for long-acting injectable medicines among people living with HIV in Japan and its associated factors: a prospective multicenter cross-sectional observational study.
Ishihara M; Hikasa S; Tsukiji M; Kunimoto Y; Nobori K; Kimura T; Onishi K; Yamamoto Y; Haruta K; Kashiwabara Y; Fujii K; Shimabukuro S; Watanabe D; Tsurumi H; Suzuki A
AIDS Res Ther; 2023 Aug; 20(1):62. PubMed ID: 37641099
[TBL] [Abstract][Full Text] [Related]
7. Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment.
Kremer IEH; Beaudart C; Simons J; Plieger H; Schroeder M; Hiligsmann M
AIDS Care; 2024 Apr; 36(4):536-545. PubMed ID: 37526109
[No Abstract] [Full Text] [Related]
8. If We Build It, Will They Come? Perceptions of HIV Cure-Related Research by People Living with HIV in Four U.S. Cities: A Qualitative Focus Group Study.
Sylla L; Evans D; Taylor J; Gilbertson A; Palm D; Auerbach JD; Dubé K
AIDS Res Hum Retroviruses; 2018 Jan; 34(1):56-66. PubMed ID: 29198134
[TBL] [Abstract][Full Text] [Related]
9. Dose-related and contextual aspects of suboptimal adherence to antiretroviral therapy among persons living with HIV in Western Europe.
Akinwunmi B; Buchenberger D; Scherzer J; Bode M; Rizzini P; Vecchio F; Roustand L; Nachbaur G; Finkielsztejn L; Chounta V; Van de Velde N
Eur J Public Health; 2021 Jul; 31(3):567-575. PubMed ID: 33462616
[TBL] [Abstract][Full Text] [Related]
10. Poor adherence to antiretroviral therapy among adult people living with HIV initiated during the COVID-19 epidemic waves - observations at the University Teaching Hospital in Lusaka, Zambia.
Kafwanka P; Nalule FM; Michelo C
Front Public Health; 2023; 11():1094214. PubMed ID: 36992897
[TBL] [Abstract][Full Text] [Related]
11. "A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania.
Kerrigan D; Sanchez Karver T; Muraleetharan O; Savage V; Mbwambo J; Donastorg Y; Likindikoki S; Perez M; Gomez H; Mantsios A; Murray M; Beckham SW; Davis W; Galai N; Barrington C
PLoS One; 2020; 15(6):e0234666. PubMed ID: 32530939
[TBL] [Abstract][Full Text] [Related]
12. Physical activity levels among Malawian adults living with HIV and receiving anti-retroviral therapy.
Chisati EM; Munthali F; Constantinou D; Lampiao F
Malawi Med J; 2020 Mar; 32(1):8-12. PubMed ID: 32733653
[TBL] [Abstract][Full Text] [Related]
13. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection.
Dandachi D; Dang BN; Lucari B; Swindells S; Giordano TP
AIDS Care; 2021 Jun; 33(6):801-809. PubMed ID: 32408771
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and/or housing instability.
Fletcher L; Burrowes SAB; Khan GK; Sabin L; Johnson S; Kimmel SD; Ruiz-Mercado G; Pierre C; Drainoni ML
Harm Reduct J; 2023 Jan; 20(1):4. PubMed ID: 36627679
[TBL] [Abstract][Full Text] [Related]
15. Preference for daily oral pills over long-acting antiretroviral therapy options among people with HIV.
Barthold D; Saldarriaga EM; Brah AT; Hauber B; Banerjee P; Fuller SM; McCaslin D; Moldoveanu AM; Marconi VC; Simoni JM; Graham SM
AIDS; 2023 Aug; 37(10):1545-1553. PubMed ID: 37289570
[TBL] [Abstract][Full Text] [Related]
16. Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial.
Murray M; Kerrigan D; Hudson KJ; Walters N; Karver TS; Mantsios A; Galai N
HIV Res Clin Pract; 2020 Aug; 21(4):105-113. PubMed ID: 33048662
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Mantsios A; Murray M; Karver TS; Davis W; Margolis D; Kumar P; Swindells S; Bredeek UF; García Del Toro M; Garcia Gasalla M; Rubio García R; Antela A; Hudson K; Griffith S; Kerrigan D
AIDS Behav; 2020 Dec; 24(12):3473-3481. PubMed ID: 32410051
[TBL] [Abstract][Full Text] [Related]
18. Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya.
Kaggiah A; Maina CN; Kinuthia J; Barthold D; Hauber B; Tran J; Simoni JM; Graham SM
BMC Infect Dis; 2024 Apr; 24(1):415. PubMed ID: 38641565
[TBL] [Abstract][Full Text] [Related]
19. Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.
Philbin MM; Parish CL; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):263-270. PubMed ID: 32530905
[TBL] [Abstract][Full Text] [Related]
20. Perceptions of HIV Virologic Control Strategies Among Younger and Older Age Groups of People Living with HIV in the United States: A Cross-Sectional Survey.
Saberi P; Eskaf S; Sauceda J; Evans D; Dubé K
AIDS Res Hum Retroviruses; 2020 Jul; 36(7):606-615. PubMed ID: 32368934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
